Location: San Francisco, CA, flexible
About Xylo:
XYLO is pioneering neuroplastogens – targeted therapies designed to rewire neural circuits and restore brain function. Combining advanced neuroscience with computationally guided drug discovery, we are developing optimized treatments to transform the lives of patients with neurological and psychiatric conditions.
Role Overview:
As the Chief Development Officer, you will own and oversee Xylo’s clinical development programs. This role bridges translational research and clinical progression, ensuring that Xylo’s pre-clinical efforts transition smoothly from drug-discovery to development. You will work closely with the leadership team, including the CEO, CSO, VP of R&D, and others to lead program strategy, operational execution, and asset advancement while acting as a forward facing thought leader to support fundraising, partnerships, and external engagement. As a hands-on member of the leadership team, you will take ownership of all aspects of the Xylo clinical team, CROs, vendors, and collaborations while fostering a culture of innovation and excellence. You will play a critical role in shaping and executing Xylo’s vision to revolutionize treatments for neurological and psychiatric conditions.
Key Responsibilities:
• Oversee and actively guide Xylo’s translational research and clinical development programs, bridging preclinical and clinical studies.
• Lead the design, execution, and oversight of international clinical trials, ensuring alignment with regulatory standards and organizational goals.
• Partner with the CSO to inform strategic decisions and provide data-driven recommendations for advancing Xylo’s scientific programs.
• Manage CROs, CMOs, and external partnerships, ensuring high-quality execution of clinical studies and a strategy that supports back-translational research for Xylo’s continued development of additional assets.
• Develop and maintain strong relationships with external stakeholders, including regulatory agencies, collaborators, and investors.
• Identify and address gaps in Xylo’s scientific and clinical strategies, contributing to hiring and team development to support key inflection points.
• Provide medical and scientific leadership across the organization, fostering a collaborative and high-performing environment.
Qualifications:
• M.D., and/or Ph.D. with expertise in clinical neuropsychiatry, translational research, and drug development. Proven leadership experience as a clinical or scientific leader in a neuro-focused biotech or pharmaceutical company.
• Experience transitioning assets from preclinical to clinical development in neuroscience is essential.
• Hands-on expertise in clinical trial design, execution, and regulatory processes (e.g., IND submissions).
• Demonstrated success in managing CROs, vendors, and collaborative research partnerships.
• Strong background engaging with external stakeholders and exceptional communication skills, with the ability to convey complex concepts to diverse audiences.
• Adaptability, and a willingness to roll up your sleeves in a fast-paced environment.
• A track record of successfully bringing assets to the clinic and navigating regulatory milestones.
Why Join Xylo?
This is a unique opportunity to lead and shape Xylo’s translational and clinical development programs during a pivotal growth phase. As CDO, you will collaborate with an exceptional team to develop transformative therapies in mental health, contribute to Xylo’s strategic vision, and drive meaningful advancements in neuroscience. If you’re energized by this opportunity but unsure if you meet every requirement, we encourage you to apply. We value diverse perspectives and experiences that can enrich our team.
Xylo is committed to maintaining a workplace free of discrimination and harassment. We celebrate diversity and promote an inclusive environment where all team members feel respected, supported, and encouraged to grow.
